Novel treatments for anaplastic thyroid carcinoma.
Anaplastic thyroid cancer (ATC)
in vitro studies
in vivo studies
molecular pathways
targeted drugs
Journal
Gland surgery
ISSN: 2227-684X
Titre abrégé: Gland Surg
Pays: China (Republic : 1949- )
ID NLM: 101606638
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
entrez:
15
2
2020
pubmed:
15
2
2020
medline:
15
2
2020
Statut:
ppublish
Résumé
Anaplastic thyroid cancer (ATC) is one of the deadliest human cancers and it is less than 2% of thyroid carcinomas (TCs). The standard treatment of ATC includes surgical debulking, accelerated hyperfractionated external beam radiation therapy (EBRT), and chemotherapy, in particular with cisplatin or doxorubicin, achieving about 10 months of median survival. Since ATC is a rare and aggressive tumor, it is still challenging to predict the patient clinical therapy responsiveness. Several genetic mutations have been described in ATC, involved in different molecular pathways linked to tumor progression, and novel therapies acting on these molecular pathways have been investigated, to improve the quality of life in these patients. Here we review the new targeted therapy of ATC. We report interesting results obtained with molecules targeting different pathways: angiogenesis (vandetanib, combretastatin, sorafenib, lenvatinib, sunitinib, CLM94, CLM3, etc.); EGFR (gefitinib, docetaxel); BRAF (dabrafenib/trametinib, vemurafenib); PPARγ agonists (rosiglitazone, pioglitazone, efatutazone); PD-1 and PD-L1 (pembrolizumab); TERT. To escape resistance to monotherapies, the evaluation of combination strategies with radiotherapy, chemotherapy, or targeted drugs is ongoing. The results of clinical trials with dabrafenib and trametinib led to the approval from FDA of this combination for patients with BRAF V600E mutated ATC with locally advanced, unresectable, or metastatic ATC. The anti-PD-L1 antibody immunotherapy, alone or combined with a BRAF inhibitor, has been shown also promising in the treatment of ATC. Furthermore, to increase the therapeutic success and not to use ineffective or even harmful treatments, a real tailored therapy should be pursued, and this can be achieved thanks to the new available genomic analysis methods and to the possibility to test in vitro novel treatments directly in primary cells from each ATC patient. Exploring new treatment strategies is mandatory to improve the survival of these patients, guaranteeing a good quality of life.
Identifiants
pubmed: 32055496
doi: 10.21037/gs.2019.10.18
pii: gs-09-S1-S28
pmc: PMC6995904
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
S28-S42Informations de copyright
2020 Gland Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Biomed Pharmacother. 2008 Oct;62(8):559-63
pubmed: 18725177
Thyroid. 2008 Mar;18(3):317-23
pubmed: 17985985
Endocrine. 2016 Jul;53(1):136-44
pubmed: 26286966
Int J Endocrinol. 2016;2016:2930414
pubmed: 27766105
Endocr Relat Cancer. 2006 Dec;13(4):1173-83
pubmed: 17158762
Int J Oncol. 2004 Jan;24(1):89-95
pubmed: 14654945
Front Endocrinol (Lausanne). 2014 Mar 25;5:37
pubmed: 24723911
Eur J Endocrinol. 2009 Dec;161(6):923-31
pubmed: 19773371
Mol Med. 2000 Aug;6(8):623-44
pubmed: 11055583
J Natl Compr Canc Netw. 2016 Mar;14(3):249-54
pubmed: 26957611
Mol Cancer Ther. 2004 Aug;3(8):1011-20
pubmed: 15299084
Int J Oncol. 2016 Dec;49(6):2303-2308
pubmed: 27748799
Crit Rev Oncol Hematol. 2015 Apr;94(1):55-63
pubmed: 25465739
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
J Clin Oncol. 2010 Feb 10;28(5):767-72
pubmed: 20065189
N Engl J Med. 2013 Feb 14;368(7):684-5
pubmed: 23406047
Gland Surg. 2019 Jun;8(3):298-300
pubmed: 31328110
Int J Exp Pathol. 2009 Jun;90(3):284-94
pubmed: 19563611
Thyroid. 2016 Oct;26(10):1515-1516
pubmed: 27532222
Thyroid. 2018 Jul;28(7):945-951
pubmed: 29742974
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Endocr Relat Cancer. 2005 Jun;12(2):291-303
pubmed: 15947104
Clin Cancer Res. 2010 Nov 1;16(21):5260-8
pubmed: 20847059
Int J Endocrinol Metab. 2019 Jan 13;17(1):e67759
pubmed: 30881466
Pathol Oncol Res. 2015 Jul;21(3):695-701
pubmed: 25588542
Int J Mol Sci. 2019 Jun 13;20(12):
pubmed: 31200515
Nat Rev Cancer. 2013 Mar;13(3):184-99
pubmed: 23429735
Endocr Relat Cancer. 2015 Dec;22(6):877-87
pubmed: 26370187
Oncotarget. 2015 Apr 20;6(11):9073-85
pubmed: 25940539
Front Endocrinol (Lausanne). 2018 Dec 18;9:764
pubmed: 30619094
Cytogenet Genome Res. 2016;150(3-4):194-207
pubmed: 28231576
Mol Biotechnol. 2007 Feb;35(2):185-97
pubmed: 17435285
J Clin Med. 2018 May 15;7(5):
pubmed: 29762469
J Clin Oncol. 2012 Jan 10;30(2):134-41
pubmed: 22025146
Expert Rev Mol Diagn. 2008 Jan;8(1):83-95
pubmed: 18088233
Thyroid. 2012 Nov;22(11):1104-39
pubmed: 23130564
J Pharmacol Exp Ther. 2012 May;341(2):410-23
pubmed: 22328572
Oncogene. 1994 Jan;9(1):281-90
pubmed: 8302590
Nat Rev Cancer. 2001 Dec;1(3):194-202
pubmed: 11902574
Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6
pubmed: 15142631
Cancer Res. 2002 Jun 15;62(12):3408-16
pubmed: 12067983
Endocrinology. 2012 Feb;153(2):985-94
pubmed: 22202162
Endocr Relat Cancer. 2009 Mar;16(1):17-44
pubmed: 18987168
Eur J Endocrinol. 2008 Sep;159(3):283-91
pubmed: 18583391
Surgery. 2012 Dec;152(6):1078-87
pubmed: 23158178
J Thyroid Res. 2014;2014:638747
pubmed: 25295214
World J Surg. 1996 Sep;20(7):867-71
pubmed: 8678964
Cancer Res. 2008 Jun 1;68(11):4183-91
pubmed: 18519677
J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400
pubmed: 23589525
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1137-43
pubmed: 15519785
Laryngoscope. 2008 Aug;118(8):1372-6
pubmed: 18475209
Oncol Rep. 2015 Apr;33(4):1994-2000
pubmed: 25683253
Surgery. 2014 Nov;156(5):1167-76
pubmed: 25151558
Biomark Insights. 2008 Apr 29;3:237-252
pubmed: 19578508
Oncotarget. 2016 Mar 29;7(13):17194-211
pubmed: 26943572
Clin Endocrinol (Oxf). 2008 Jul;69(1):148-52
pubmed: 18194485
J Clin Endocrinol Metab. 2014 Apr;99(4):E572-81
pubmed: 24423321
Cancer Res. 2009 Feb 15;69(4):1536-44
pubmed: 19208833
Lancet Oncol. 2004 Jul;5(7):419-29
pubmed: 15231248
J Clin Endocrinol Metab. 2015 Jan;100(1):35-42
pubmed: 25347569
Lancet Oncol. 2012 Sep;13(9):897-905
pubmed: 22898678
J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16
pubmed: 18492751
J Clin Endocrinol Metab. 2011 Mar;96(3):766-74
pubmed: 21123448
Cancers (Basel). 2019 Jul 04;11(7):
pubmed: 31277524
Clin Endocrinol (Oxf). 2009 Jun;70(6):946-53
pubmed: 18785992
Oncol Rep. 2018 May;39(5):2306-2314
pubmed: 29517106
Thyroid. 2017 Sep;27(9):1142-1148
pubmed: 28635560
Clin Cancer Res. 2007 Feb 15;13(4):1161-70
pubmed: 17317825
Br J Cancer. 2001 May 18;84(10):1289-90
pubmed: 11355935
Nat Commun. 2019 Jun 24;10(1):2764
pubmed: 31235699
J Clin Oncol. 2009 Apr 1;27(10):1675-84
pubmed: 19255327
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
Ann Oncol. 2015 Feb;26(2):354-62
pubmed: 25467017
J Clin Endocrinol Metab. 2012 Apr;97(4):E528-36
pubmed: 22278419
Eur J Cancer. 2017 May;76:110-117
pubmed: 28301826
Mol Cell Endocrinol. 2018 Jul 5;469:23-37
pubmed: 28552796
Thyroid. 2018 Jan;28(1):79-87
pubmed: 29161986
Front Endocrinol (Lausanne). 2016 Feb 29;7:20
pubmed: 26973599
J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71
pubmed: 20371662
Genes (Basel). 2016 May 26;7(6):
pubmed: 27240403
J Res Med Sci. 2013 Jul;18(7):623-5
pubmed: 24516498
Acta Derm Venereol. 2015 May;95(5):516-24
pubmed: 25520039
Thyroid. 2013 May;23(5):600-4
pubmed: 23113752
Endocr Relat Cancer. 2005 Jun;12(2):245-62
pubmed: 15947100
Future Oncol. 2019 Mar;15(7):717-726
pubmed: 30638399
Sci Transl Med. 2017 Jul 26;9(400):
pubmed: 28747513
Endocr Relat Cancer. 2017 Feb;24(2):97-106
pubmed: 28093480
Endocr Rev. 2004 Aug;25(4):581-611
pubmed: 15294883
Oncol Lett. 2018 Dec;16(6):7271-7277
pubmed: 30546466
Am J Pathol. 1999 Dec;155(6):1967-76
pubmed: 10595926
Endocrinol Metab (Seoul). 2018 Mar;33(1):121-132
pubmed: 29589394
J Clin Endocrinol Metab. 1999 Nov;84(11):4043-9
pubmed: 10566647
Cancer. 2017 Nov 1;123(21):4114-4121
pubmed: 28662274
Endocrinology. 2006 Sep;147(9):4463-75
pubmed: 16777971
Endocr J. 2001 Dec;48(6):635-46
pubmed: 11873861
Clin Cancer Res. 2012 Jul 15;18(14):3722-30
pubmed: 22665903
Biotechnol Biotechnol Equip. 2014 May 4;28(3):508-517
pubmed: 26019537
Surgery. 2012 Dec;152(6):1088-9
pubmed: 23158179
Onco Targets Ther. 2016 Nov 11;9:6965-6976
pubmed: 27956840
Eur J Cancer. 1990;26(7):834-8
pubmed: 2145907
Surgery. 2001 May;129(5):552-8
pubmed: 11331447
J Clin Oncol. 2018 Jan 1;36(1):7-13
pubmed: 29072975
Eur Ann Otorhinolaryngol Head Neck Dis. 2014 Feb;131(1):7-13
pubmed: 23845288
J Immunother Cancer. 2018 Jul 11;6(1):68
pubmed: 29996921
Oncol Rep. 2018 May;39(5):2225-2234
pubmed: 29517103
Curr Med Chem. 2019;26(6):963-972
pubmed: 28990511
J Clin Endocrinol Metab. 2006 Oct;91(10):4070-6
pubmed: 16849418
PLoS One. 2014 May 23;9(5):e96103
pubmed: 24858712
J Surg Res. 2013 Dec;185(2):676-83
pubmed: 23845866
Langenbecks Arch Surg. 2007 Jul;392(4):397-404
pubmed: 17131154
J Clin Oncol. 2008 Oct 10;26(29):4714-9
pubmed: 18541894
J Clin Endocrinol Metab. 2014 Nov;99(11):E2178-87
pubmed: 25078145
Thyroid. 2019 Jul;29(7):979-992
pubmed: 30938231
Cancer. 2005 Jun 1;103(11):2261-8
pubmed: 15880523
Thyroid. 2011 Nov;21(11):1171-4
pubmed: 22050034
Curr Genomics. 2011 Dec;12(8):626-31
pubmed: 22654562
Br J Cancer. 2005 Mar 28;92(6):1110-6
pubmed: 15785737
Thyroid. 2014 Feb;24(2):232-40
pubmed: 23721245
Cancer Biol Ther. 2015;16(10):1430-3
pubmed: 26176686
Cancer. 1998 Dec 15;83(12):2638-48
pubmed: 9874472
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
J Clin Endocrinol Metab. 2001 May;86(5):2170-7
pubmed: 11344222
J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9
pubmed: 18682506
Thyroid. 2005 Mar;15(3):222-31
pubmed: 15785241
Mol Cancer. 2018 Nov 22;17(1):164
pubmed: 30466442
Oncol Lett. 2016 Oct;12(4):2254-2260
pubmed: 27698787
Thyroid. 2013 Oct;23(10):1277-83
pubmed: 23489023